Lactobacillus brevis CD2 lozenges have been shown to reduce the severity and incidence of radio/chemotherapy-induced mucositis in head and neck cancer patients, thereby increasing the likelihood of anticancer treatment completion [118]. This evidence concerns the gene CD2 and mucositis.